Abstract
Background: Oxidized Low-Density Lipoprotein (ox-LDL) is crucial in the recrudescence and prognosis of acute ischemic stroke (AIS). We aimed to probe into the influence of cumulative ox-LDL exposure on the 90-day prognosis of AIS.
Methods: Patients with AIS were recruited in this research. AIS severity at admission was estimated with infarct volumes and National Institute of Health Stroke Scale (NIHSS) scores. AIS prognosis was assessed using Modified Rankin Scale (mRS) scores at 90 days and the change in NIHSS scores from admission to discharge. Cumulative ox-LDL exposure was defined as ox-LDL level (pg/mL) multiplied by age(y). Multivariate logistic regression analysis was employed to reveal the correlation between exposure factors and the prognosis of AIS. The prognostic prediction ability of cumulative ox-LDL exposure was compared with cumulative LDL exposure by the receiver operating characteristic curve (ROC).
Results: Higher cumulative ox-LDL exposure was related to worse prognosis, including neurological worsening at discharge (NIHSS increasing more than 2 points) (OR = 3.02, 95% CI, 1.30-6.98, P = 0.01) and poor functional prognosis at 90 days (mRS ≥ 3) (OR = 21.21, 95% CI, 4.72-95.36, P < 0.001). As multivariate regression analysis showed, significantly increased cumulative ox-LDL exposure was relevant to poor functional prognosis at 90 days (OR = 9.92, 95% CI, 1.23-79.76, P = 0.031), but not with neurological worsening at discharge (P = 0.414). ROC curve revealed that cumulative ox-LDL exposure had a higher predictive value (AUC = 0.843, P < 0.001) for functional prognosis of AIS than cumulative LDL exposure (AUC = 0.629, P = 0.023).
Conclusion: Cumulative ox-LDL exposure has a positive correlation with poor prognosis at 90 days of AIS, and has a more accurate predictive ability than cumulative LDL exposure.
[http://dx.doi.org/10.1016/S1474-4422(21)00252-0] [PMID: 34487721]
[http://dx.doi.org/10.1161/CIR.0000000000000558] [PMID: 29386200]
[http://dx.doi.org/10.1016/S2468-2667(21)00228-0] [PMID: 34838196]
[http://dx.doi.org/10.1016/S0140-6736(20)30925-9] [PMID: 33069326]
[http://dx.doi.org/10.1136/jnnp.53.1.16] [PMID: 2303826]
[http://dx.doi.org/10.1161/hc0902.104353] [PMID: 11877368]
[http://dx.doi.org/10.1038/nchembio.85] [PMID: 18421291]
[http://dx.doi.org/10.3389/fphar.2020.613780] [PMID: 33510639]
[http://dx.doi.org/10.3389/fcvm.2022.925923] [PMID: 35722128]
[http://dx.doi.org/10.1212/WNL.0000000000006118] [PMID: 30089614]
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.01.028] [PMID: 29407884]
[http://dx.doi.org/10.1161/STROKEAHA.116.014816] [PMID: 27899755]
[http://dx.doi.org/10.1155/2021/4998823] [PMID: 34950249]
[http://dx.doi.org/10.1016/j.jacc.2018.06.046] [PMID: 30165986]
[http://dx.doi.org/10.1161/01.STR.20.7.864] [PMID: 2749846]
[http://dx.doi.org/10.1161/STROKEAHA.120.033187] [PMID: 34412513]
[http://dx.doi.org/10.1016/j.neuroimage.2006.01.015] [PMID: 16545965]
[http://dx.doi.org/10.1161/01.STR.24.7.1000] [PMID: 8322373]
[http://dx.doi.org/10.1161/STROKEAHA.108.543587] [PMID: 19407233]
[http://dx.doi.org/10.3171/2022.5.JNS22589] [PMID: 35901703]
[http://dx.doi.org/10.1161/01.CIR.104.3.365] [PMID: 11457759]
[http://dx.doi.org/10.1124/pharmrev.120.000096] [PMID: 34088867]
[http://dx.doi.org/10.1161/01.CIR.101.13.1500] [PMID: 10747340]
[http://dx.doi.org/10.1161/ATVBAHA.111.237263] [PMID: 21998134]
[http://dx.doi.org/10.1016/j.atherosclerosis.2021.05.019] [PMID: 34118596]
[http://dx.doi.org/10.1111/jth.13925] [PMID: 29316215]
[http://dx.doi.org/10.1111/j.1749-6632.2001.tb03941.x] [PMID: 11795267]
[http://dx.doi.org/10.1073/pnas.97.1.360] [PMID: 10618423]
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.115287] [PMID: 18645046]
[http://dx.doi.org/10.1042/CS20030152] [PMID: 12837127]
[http://dx.doi.org/10.1042/cs1010523] [PMID: 11672458]
[http://dx.doi.org/10.1016/j.metabol.2007.01.018] [PMID: 17570246]
[http://dx.doi.org/10.1161/hs0302.103619] [PMID: 11872902]